Pluristem Therapeutics (NASDAQ:PSTI) and Gritstone Oncology (NASDAQ:GRTS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.
This is a summary of recent recommendations for Pluristem Therapeutics and Gritstone Oncology, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Pluristem Therapeutics currently has a consensus price target of $3.83, suggesting a potential upside of 552.82%. Gritstone Oncology has a consensus price target of $22.20, suggesting a potential upside of 126.07%. Given Pluristem Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Pluristem Therapeutics is more favorable than Gritstone Oncology.
Insider & Institutional Ownership
6.0% of Pluristem Therapeutics shares are held by institutional investors. Comparatively, 48.8% of Gritstone Oncology shares are held by institutional investors. 6.7% of Pluristem Therapeutics shares are held by company insiders. Comparatively, 38.0% of Gritstone Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares Pluristem Therapeutics and Gritstone Oncology’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Pluristem Therapeutics and Gritstone Oncology’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Pluristem Therapeutics||$50,000.00||1,707.34||-$26.12 million||($0.25)||-2.35|
|Gritstone Oncology||$1.19 million||294.76||-$64.78 million||($7.26)||-1.35|
Pluristem Therapeutics has higher earnings, but lower revenue than Gritstone Oncology. Pluristem Therapeutics is trading at a lower price-to-earnings ratio than Gritstone Oncology, indicating that it is currently the more affordable of the two stocks.
Gritstone Oncology beats Pluristem Therapeutics on 7 of the 12 factors compared between the two stocks.
About Pluristem Therapeutics
Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies; a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has a collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.
About Gritstone Oncology
Gritstone Oncology Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. Gritstone Oncology Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.